Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, announces that it has co-led a $45 million Series B financing round in Nuevocor, an IND-stage biotechnology company specialized in the development of transformative therapies for patients with  genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects.

Founded in 2021, Nuevocor is pioneering a new generation of pathway-specific genetic medicines using its PrOSIA mechanobiology platform, with the potential to benefit patients across multiple cardiac genetic disorders. The company is dedicated to transforming the treatment of genetic cardiomyopathies by addressing the biomechanical root causes of the disease. Proceeds from the financing will be used to achieve clinical proof-of-concept for its lead candidate NVC-001 in patients with LMNA DCM, a rare genetic heart condition caused by mutations in the LMNA gene.

Angelini Ventures co-led the financing with Kurma Partners and participation from Highlight Capital as well as continued significant support from existing investors Boehringer Ingelheim Venture Fund, ClavystBio, EDBI, SEEDS Capital and Xora Innovation.

Dr. Elia Stupka, Managing Director at Angelini Ventures, will join Nuevocor’s Board of Directors as Board member, together with Dr. Lola Buono, Senior Associate, who will join as a Board Observer.

Angelini Ventures has partnered with Nuevocor, reflecting its vision to support transformative global biotech companies with the potential to become the next generation of biopharma leaders. This collaboration marks Angelini Ventures’ first investment in the cardiovascular space and in gene therapy as well as the first investment in Asia - unlocking access to cutting edge innovation and transformative potential for patient outcomes.

Dr. Elia Stupka, Managing Director at Angelini Ventures said, “This investment represents a significant strategic milestone for Angelini Ventures. It not only broadens our global footprint to a strategic Asian Life Sciences Hub such as Singapore but also accelerates our mission to back transformative science with the potential to impact patients worldwide. We’re excited by Nuevocor’s novel approach to treating genetic dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes. This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens. We’re proud to support Nuevocor’s mission and join the board - alongside Kurma Partners - as the company expands its global presence and advances clinical development in Europe.”

“We are delighted to secure this significant financing milestone and build global collaborations with such an experienced syndicate of life sciences investors. Their support will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic,” said Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor. “There exists a huge unmet need for patients suffering from cardiomyopathies, and with the help of our powerful mechanobiology platform, we continue to build our pipeline of targeted life-changing medicines for these patients.”